{"gene":"CD59","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1992,"finding":"CD59 binds specifically to the alpha-chain of C8 and to the C9b domain (37-kDa fragment) of C9, but not to C8 beta, C8 gamma, C9a, C5b6, or C7, establishing that CD59 inhibits MAC assembly through direct protein-protein interactions with these specific complement components.","method":"Radiolabeled (125I) CD59 binding assays to surface-adsorbed complement proteins, ligand blotting after SDS-PAGE separation of C8 subunits, and thrombin digestion of C9; saturable binding with defined Kd values","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution binding assay with radiolabeled ligand, subunit dissection, proteolytic mapping, and saturable kinetics; single rigorous study with multiple orthogonal methods","pmids":["1377690"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of inhibited MAC precursors C5b8 and C5b9 reveal that CD59 binds the pore-forming β-hairpins of C8 to form an intermolecular β-sheet that prevents membrane perforation; while bound to C8, CD59 deflects cascading C9 β-hairpins into the membrane rather than allowing polymerization, thereby restricting structural transitions of subsequent C9 monomers and indirectly halting MAC polymerization.","method":"Cryo-electron microscopy structures of C5b8:CD59 and C5b9:CD59 complexes, combined with cellular complement lysis assays and molecular dynamics simulations","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structures with multiple complexes, validated by cellular assays and MD simulations in one study","pmids":["36797260"],"is_preprint":false},{"year":2001,"finding":"Targeted gene deletion of CD59 in mice causes spontaneous intravascular hemolysis: CD59-deficient erythrocytes show increased susceptibility to complement in vitro, and mice have elevated reticulocyte counts plus hemoglobin in plasma and urine, demonstrating that CD59 is required in vivo to protect erythrocytes from MAC-mediated lysis.","method":"Gene targeting in embryonic stem cells to generate CD59-knockout mice; in vitro acidified serum lysis test; reticulocyte counts; plasma and urine hemoglobin measurements; cobra venom factor challenge","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple orthogonal phenotypic readouts (lysis assay, reticulocyte counts, hemoglobin measurements), replicated across conditions","pmids":["11435315"],"is_preprint":false},{"year":1992,"finding":"CD59 functions as a second ligand for the T cell surface molecule CD2: CHO cells expressing human CD59 form rosettes with human T cells inhibitable by anti-CD59 and anti-CD2 antibodies; radiolabeled CD59 binds specifically to CD2-expressing cells; and CD59 binding to T cells induces expression of CD2R epitopes, indicating a direct CD59–CD2 adhesion interaction.","method":"CHO cell transfection with CD59 cDNA; rosette assay with antibody blocking; 125I-labeled CD59 binding to CD2+ transfectants; CD2R epitope induction assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional assays (rosette inhibition, radiolabeled ligand binding, epitope induction) in a single study with multiple orthogonal methods","pmids":["1385156"],"is_preprint":false},{"year":1992,"finding":"CD59 is physically associated in a detergent-resistant complex with an 80-kDa glycoprotein, CD55, and glycolipids on HPB ALL cells; the complex also contains protein kinase activity, suggesting CD59 participates in GPI-anchored membrane signaling complexes.","method":"Co-immunoprecipitation from detergent lysates with anti-CD59 and anti-CD55 mAbs; SDS-PAGE analysis; protein kinase activity assay of immunoprecipitates","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP approach with kinase activity follow-up in one lab; complex not fully characterized","pmids":["1715364"],"is_preprint":false},{"year":1992,"finding":"CD59 and CD58 exhibit additive/synergistic roles in T cell adhesion and activation: CD59-expressing CHO transfectants alone induce T cell rosettes and sevenfold proliferation enhancement, while double CD58+CD59 transfectants produce >40-fold enhancement—far exceeding the sum of single transfectants—demonstrating direct costimulatory function of CD59.","method":"Stable CHO cell transfectants expressing CD59, CD58, or both; rosette assay; T cell proliferation assay with submitogenic PHA + IL-1","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean transfection system with two functional readouts (adhesion, proliferation), single lab","pmids":["1370512"],"is_preprint":false},{"year":1994,"finding":"CD59 costimulation of T cell activation requires CD58 co-expression and N-glycosylation at Asn18: CD59 enhanced CD58-dependent proliferation and IL-2 secretion, but a glycosylation-deficient CD59 (mutated at Asn18) abolished this costimulatory activity, while CD59 alone without CD58 could not support proliferation.","method":"CHO transfectants expressing rCD58, rCD59, or both; site-directed mutagenesis of N-glycosylation site Asn18; T cell proliferation and IL-2 secretion assays with paraformaldehyde-fixed transfectants","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with functional reconstitution assays establishing glycosylation requirement; single lab with multiple orthogonal methods","pmids":["7521361"],"is_preprint":false},{"year":2003,"finding":"CD59 functions as a co-receptor in human NK cell activation: CD59 is physically associated with NKp46 and NKp30 (natural cytotoxicity receptors), and antibody engagement of CD59 enhances NK cytotoxicity in an NKp46-dependent manner, triggering tyrosine phosphorylation of CD3ζ chains associated with NKp46 and NKp30 but not CD16.","method":"Co-immunoprecipitation of CD59 with NCRs; NK cytotoxicity assays with anti-CD59 mAb; NKp46 modulation experiments; biochemical phosphorylation analysis of CD3ζ chains","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, functional cytotoxicity assays, and signaling analysis (ζ-chain phosphorylation) in one study with multiple orthogonal methods","pmids":["14635045"],"is_preprint":false},{"year":2014,"finding":"CD59 regulates insulin secretion through intracellular interactions with exocytotic SNARE proteins VAMP2 and Syntaxin-1: most CD59 in pancreatic β-cells is intracellular; silencing intracellular CD59 markedly suppresses regulated exocytosis, while removing extracellular CD59 only moderately stimulates secretion; CD59 co-immunoprecipitates with VAMP2 and Syntaxin-1.","method":"Co-immunoprecipitation of CD59 with VAMP2 and Syntaxin-1; siRNA silencing of CD59; TIRF microscopy imaging of exocytosis; PI-PLC cleavage to remove extracellular CD59; insulin secretion assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP of binding partners, TIRF live-cell imaging, and loss-of-function assays in one study with multiple orthogonal methods","pmids":["24726385"],"is_preprint":false},{"year":2022,"finding":"Alternative splicing of the CD59 gene produces non-GPI-anchored cytosolic isoforms (IRIS-1 and IRIS-2) in human pancreatic β-cells that interact with SNARE proteins VAMP2 and SNAP25, colocalize with insulin granules, and rescue insulin secretion in CD59-knockout cells; CRISPR/Cas9 knockout of the mouse intracellular isoforms (not canonical CD59B) specifically abrogates insulin secretion.","method":"RT-PCR and sequencing of CD59 splice variants; co-immunoprecipitation with VAMP2 and SNAP25; confocal colocalization with insulin granules; CD59-KO cell rescue experiments; CRISPR/Cas9 knockout of mouse isoforms; insulin secretion assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — molecular cloning, Co-IP, CRISPR knockout with rescue, and functional secretion assays; multiple orthogonal methods in one study","pmids":["35666870"],"is_preprint":false},{"year":1997,"finding":"N-glycosylation of rat CD59 is not required for complement-inhibitory function: a point-mutant lacking the N-glycosylation site at Asn-16 (reducing MW from ~20-28 kDa to ~12 kDa) retains at least as potent complement-inhibitory activity as the wild-type molecule.","method":"Site-directed mutagenesis of N-glycosylation site; expression in CHO cells; complement lysis assay with multiple species' sera; antibody blocking confirmation","journal":"Immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional reconstitution in CHO cells, antibody-blocking controls; single lab with clean mechanistic result","pmids":["9176120"],"is_preprint":false},{"year":2006,"finding":"CD59-mediated NK cell activation and enhanced target cell susceptibility to NK killing requires GPI anchor-dependent signaling: GPI-anchored CD59 (by transfection or membrane incorporation) increases NK cytotoxicity against target cells, whereas CD59 anchored via a bis-myristoylated peptide or a transmembrane domain does not, despite similar lipid raft localization; unglycosylated GPI-anchored CD59 retains this activity, confirming GPI anchor dependence and glycosylation independence.","method":"CD59 transfection and membrane incorporation with different anchor types (GPI, BiMP, transmembrane) in U937 cells; NK cytotoxicity assays; calcium flux assays after CD59 cross-linking; lipid raft fractionation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple anchor variants tested functionally, calcium signaling readout, lipid raft analysis; single lab with multiple orthogonal approaches","pmids":["16493049"],"is_preprint":false},{"year":2006,"finding":"Cross-linking of CD59 on Jurkat T cells induces cell death via preferential secretion of APO2L/TRAIL (not FasL or TRAIL), distinct from TCR-mediated AICD which uses both FasL and TRAIL; this was confirmed in normal human T cell blasts where anti-CD59 cross-linking supernatants were toxic in a manner fully blocked by anti-APO2L antibody.","method":"Anti-CD59 antibody cross-linking on Jurkat and J.RT3.T3.5 cells; blocking antibodies against FasL, TRAIL, and anti-APO2L; cytotoxicity assays on supernatants; normal T cell blasts confirmation","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cross-linking with defined blocking antibodies establishing TRAIL specificity; single lab","pmids":["10760796"],"is_preprint":false},{"year":1993,"finding":"CD59 expression on endothelial cells is upregulated at the transcriptional level by PKC activators (PMA) and PKA activators (db-cAMP), with functional consequence of increased resistance to complement-mediated lysis; Northern blot showed increases in CD59 mRNA (particularly 1.9, 2.1, and 5.8 kb transcripts).","method":"PKC and PKA agonist treatment of EA.hy 926 endothelial cells; flow cytometry of surface CD59; Northern blot analysis; complement lysis assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — expression regulation with functional lysis assay follow-up; multiple agonists tested in one lab","pmids":["7691609"],"is_preprint":false},{"year":1993,"finding":"Enhanced CD59 (MIRL) expression in response to PMA is regulated at the level of transcription and requires de novo protein synthesis: PMA-induced CD59 RNA upregulation was abrogated by both a protein synthesis inhibitor and a transcription inhibitor, consistent with induction of a trans-acting factor that promotes CD59 transcription.","method":"PMA stimulation of K562 cells; Northern blot for CD59 RNA; immunoprecipitation and Western blot for CD59 protein; cycloheximide (protein synthesis inhibitor) and actinomycin D (transcription inhibitor) experiments","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcription and translation inhibitor experiments with mRNA and protein readouts; single lab","pmids":["7687899"],"is_preprint":false},{"year":2006,"finding":"CD59 expression is regulated by p53: p53 binds two putative p53-responsive elements in the CD59 gene in vitro; p53 knockdown by siRNA reduces CD59 protein expression sixfold in HeLa cells; acetylation status of p53 modulates CD59 expression in cells exposed to inflammatory cytokines.","method":"In vitro p53 binding to CD59 gene p53-responsive elements; siRNA knockdown of p53; Western blot of CD59 protein; acetylation status analysis; camptothecin-induced apoptosis model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro DNA binding plus siRNA knockdown with protein readout; single lab","pmids":["16489052"],"is_preprint":false},{"year":2006,"finding":"CD59 expression in neurons is regulated by the neural-restrictive silencer factor (REST), which represses CD59 transcription; a REST-derived peptide (REST5) containing the nuclear localization domain upregulates CD59 expression fivefold in neurons and protects them from complement-mediated lysis.","method":"REST peptide transfection in neuroblastoma cells and human neurons differentiated from neural progenitor cells; CD59 expression measurements; complement lysis assays with human serum or oligodendroglia-conditioned medium","journal":"The pharmacogenomics journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic REST peptide intervention with expression and functional readouts; single lab","pmids":["19884909"],"is_preprint":false},{"year":2016,"finding":"SOX2 transcription factor upregulates CD59 expression in epithelial cancer stem cells to protect them from complement-dependent cytotoxicity; CD59 silencing in cancer stem cells enhanced complement-mediated destruction and suppressed tumorigenesis in xenograft models; SOX2 also regulates mCd59b transcription in murine testis spermatogonial stem cells.","method":"CD59 and SOX2 siRNA silencing; sphere-forming cancer stem cell preparation; complement lysis assays; xenograft tumorigenesis in nude mice; SOX2-CD59 transcriptional regulation analysis","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with in vivo xenograft confirmation and transcriptional regulation data; single lab","pmids":["28017655"],"is_preprint":false},{"year":2016,"finding":"Intermedilysin (ILY) binds CD59 to coordinate monomer assembly and trigger collapse of an oligomeric prepore: CD59 is required for specific coordination of ILY monomers; movement of ILY Domain 2 relative to Domain 3 forms a late prepore intermediate that releases CD59, while cholesterol mediates transmembrane segment insertion.","method":"Biochemical binding assays; electron microscopy; atomic force microscopy of ILY pore formation intermediates","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EM and AFM structural analysis combined with biochemical assays defining stepwise mechanism; single lab with multiple orthogonal methods","pmids":["27910935"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of vaginolysin and intermedilysin (CD59-responsive cholesterol-dependent cytolysins) complexed with CD59 show that each toxin binds CD59 at different but overlapping sites; the proline substitution in the CDC undecapeptide consensus motif acts as a selectivity switch ensuring CD59-dependent CDCs bind CD59 before cholesterol.","method":"X-ray crystal structures of VLY:CD59 and ILY:CD59 complexes; small-angle X-ray scattering; molecular dynamics simulations; binding studies","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — two independent crystal structures validated by SAXS and MD simulations; single study, multiple orthogonal methods","pmids":["27499440"],"is_preprint":false},{"year":2015,"finding":"CD59 receptor signaling drives Syk-dependent erythrocyte necroptosis: binding or crosslinking of CD59 leads to Syk-dependent echinocyte formation with Band 3 phosphorylation and FasL release; FasL-dependent phosphorylation of RIP1, combined with membrane pore formation, triggers RIP3 phosphorylation and necroptosis execution.","method":"CD59 antibody crosslinking; human CD59-targeted pore-forming toxin treatment; Syk inhibition; FasL blocking antibody; phosphorylation analysis of Band 3, RIP1, RIP3; cell death assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — signaling pathway dissection with specific inhibitors and phosphorylation readouts; single lab","pmids":["26018734"],"is_preprint":false},{"year":2010,"finding":"CD59 protects against abdominal aortic aneurysm development: CD59-deficient mice develop more severe angiotensin II-induced aneurysms with increased C9 deposition, MMP2/9 activity, and phosphorylated AP-1/NF-κB components; transgenic human CD59 overexpression attenuates aneurysm progression; MAC directly induces MMP-2 and MMP-9 gene expression in vitro through AP-1 and NF-κB pathways.","method":"CD59 knockout and human CD59 transgenic mice in ApoE-null angiotensin II aneurysm model; C9 deposition measurement; MMP2/9 activity assays; phosphorylation of AP-1/NF-κB components; in vitro MAC stimulation of gene expression","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary KO and transgenic overexpression with defined downstream signaling readouts; single lab","pmids":["20212283"],"is_preprint":false},{"year":2021,"finding":"CD59 is an integral component of the LecA-Gb3 lipid raft membrane domain in P. aeruginosa invasion: flotillins and CD59 co-purify with the LecA-interacting domain by pulldown and mass spectrometry; depletion of CD59 reduces PAO1 bacterial invasiveness by ~50%.","method":"Pulldown and mass spectrometry of LecA-associated membrane domain; CD59 depletion; bacterial invasion assay measuring P. aeruginosa PAO1 uptake","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry identification plus functional depletion assay; single lab","pmids":["33555391"],"is_preprint":false},{"year":1994,"finding":"Transmembrane-anchored recombinant CD59 expressed on GPI-anchoring deficient PNH B cells confers resistance to complement-mediated lysis, demonstrating that GPI anchoring is not strictly required for CD59 complement-inhibitory function; however, GPI-anchored CD59 cannot be expressed on GPI-deficient L cells while transmembrane CD59 can.","method":"Retroviral transduction of transmembrane CD59 (CD59-TM) construct into GPI-deficient PNH B cells and mouse L cells; complement lysis assay with human serum; PI-PLC treatment to confirm membrane anchor type; flow cytometry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution in disease-relevant PNH cells with complement lysis assay; single lab","pmids":["7522635"],"is_preprint":false},{"year":1992,"finding":"CD59 gene has a structure of one 5'-untranslated exon and three coding exons spanning >27 kb, and produces multiple mRNA isoforms (>4) through alternative polyadenylation at distinct sites in the 3' region.","method":"Genomic library cloning; Southern blotting; Northern blot with six different 3'-region probes; RACE (rapid amplification of cDNA ends)","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic cloning and multiple Northern probes establishing gene structure and polyadenylation; single lab","pmids":["1383553"],"is_preprint":false},{"year":2018,"finding":"CD59 deficiency promotes radioresistance of esophageal cancer cells through Src kinase activation: CD59 deficiency exacerbates DNA damage, impairs DNA damage repair, induces G2/M arrest and senescence, and reduces Src phosphorylation at Y416 after ionizing radiation; pharmacological Src inhibition sensitizes cells to radiation.","method":"CD59 knockdown/overexpression in ESCC cell lines; irradiation; DNA damage assays (γ-H2AX); cell cycle analysis; senescence assay; Western blot for phospho-Src Y416; Src inhibitor saracatinib treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with mechanistic Src signaling readout and pharmacological validation; single lab","pmids":["30166523"],"is_preprint":false},{"year":2012,"finding":"A homozygous p.Cys89Tyr missense mutation in CD59 causes failure of proper CD59 localization to the cell surface membrane, resulting in congenital chronic hemolysis and relapsing peripheral demyelinating polyneuropathy; mutant protein is present intracellularly but undetectable on the membrane surface by flow cytometry and Western blot.","method":"Homozygosity mapping, exome sequencing, Sanger sequencing; flow cytometry for CD59/CD55/CD14 surface expression; Western blot of CD59 protein","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic mapping with protein localization analysis; single study","pmids":["23149847"],"is_preprint":false},{"year":2018,"finding":"All four known CD59 congenital mutations generate nonfunctional CD59 that fails to inhibit MAC formation; two missense mutants (p.Cys64Tyr and p.Asp24Val) reach the cell surface but are not recognized by known anti-CD59 antibodies; two frameshift mutants remain intracellular; all mutants show normal glycosylation but mutant-specific secretion patterns.","method":"Cloning and expression of all four mutants in plasmids; myc-tag immunolabeling; anti-CD59 antibody labeling; Western blot for glycosylation; complement lysis (MAC-dependent cell lysis) assays; secretion analysis","journal":"Neurology. Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic expression and functional characterization of all four mutants with multiple readouts; single lab","pmids":["30533526"],"is_preprint":false},{"year":1999,"finding":"An antibody–CD59 fusion protein (IgG-CD59) targeted to cell surfaces via antigen binding provides complement protection specifically to antigen-positive cells but not bystander cells; CD59 must be positioned in close proximity to MAC formation sites for effective function, and non-GPI membrane attachment modes affect CD59 activity.","method":"Construction and expression of IgG-CD59 chimeric fusion proteins with CD59 at different Ig region positions; binding to dansyl-labeled CHO cells; complement lysis protection assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution with targeted delivery establishing spatial requirement; single lab","pmids":["9884334"],"is_preprint":false}],"current_model":"CD59 is a GPI-anchored glycoprotein that protects host cells from complement-mediated lysis by binding directly to the β-hairpins of C8 (α-chain) and C9 (C9b domain) within assembling MAC complexes, forming an intermolecular β-sheet that blocks membrane perforation and halts C9 polymerization (established by radiolabel binding assays and cryo-EM structures); it additionally functions as a CD2 co-ligand mediating T cell adhesion and costimulation (requiring N-glycosylation at Asn18 and CD58 co-expression), as an NK cell co-receptor physically associated with NKp46/NKp30 whose GPI anchor-dependent signaling enhances cytotoxicity, and as an intracellular regulator of insulin secretion through alternatively spliced non-GPI isoforms (IRIS-1/2) that interact with exocytotic SNARE proteins VAMP2, Syntaxin-1, and SNAP25 in pancreatic β-cells; its expression is transcriptionally regulated by p53, REST, and SOX2, and loss-of-function (genetic KO or human mutations) causes spontaneous intravascular hemolysis and, in humans, demyelinating neuropathy due to uncontrolled MAC formation."},"narrative":{"mechanistic_narrative":"CD59 is a GPI-anchored cell-surface glycoprotein whose primary role is to protect host cells from complement-mediated lysis by restricting assembly of the membrane attack complex (MAC) [PMID:1377690, PMID:11435315]. It acts through direct protein-protein contacts, binding specifically to the alpha-chain of C8 and the C9b domain of C9 but not other complement subunits [PMID:1377690]; cryo-EM of inhibited C5b8 and C5b9 precursors shows that CD59 engages the pore-forming β-hairpins of C8 to form an intermolecular β-sheet that prevents membrane perforation and deflects cascading C9 β-hairpins to halt polymerization [PMID:36797260]. This protective function is physiologically essential: CD59 knockout mice undergo spontaneous intravascular hemolysis from MAC-mediated erythrocyte destruction [PMID:11435315], and a homozygous p.Cys89Tyr mutation that prevents CD59 surface localization causes congenital chronic hemolysis with relapsing demyelinating polyneuropathy in humans [PMID:23149847], with all characterized congenital mutants failing to inhibit MAC formation [PMID:30533526]. Complement inhibition requires correct membrane positioning rather than glycosylation, since unglycosylated and even transmembrane-anchored CD59 retain inhibitory activity when appropriately localized [PMID:9176120, PMID:7522635, PMID:9884334]. Beyond complement regulation, CD59 serves several signaling and adhesion roles: it is a second ligand for the T-cell receptor CD2, driving adhesion and CD58-dependent, Asn18-glycosylation-dependent costimulation [PMID:1385156, PMID:7521361]; it physically associates with the NK natural cytotoxicity receptors NKp46 and NKp30 and enhances cytotoxicity through GPI-anchor-dependent signaling [PMID:14635045, PMID:16493049]; and CD59 cross-linking triggers death signaling via APO2L/TRAIL secretion in T cells and Syk-dependent necroptosis in erythrocytes [PMID:10760796, PMID:26018734]. A distinct intracellular function is exercised by alternatively spliced non-GPI cytosolic isoforms (IRIS-1/IRIS-2) that bind the exocytotic SNARE proteins VAMP2, Syntaxin-1, and SNAP25 to drive regulated insulin secretion in pancreatic β-cells [PMID:24726385, PMID:35666870]. CD59 is also exploited as a receptor by the CD59-dependent cholesterol-dependent cytolysins intermedilysin and vaginolysin, which bind CD59 to coordinate prepore assembly [PMID:27910935, PMID:27499440]. Its expression is transcriptionally controlled by p53, REST, and SOX2 [PMID:16489052, PMID:19884909, PMID:28017655].","teleology":[{"year":1992,"claim":"Established the molecular basis of complement inhibition by defining exactly which MAC components CD59 contacts, moving the field from a phenomenological 'protectin' to a defined molecular interaction.","evidence":"Radiolabeled CD59 binding assays, ligand blotting of C8 subunits, and proteolytic mapping of C9 in vitro","pmids":["1377690"],"confidence":"High","gaps":["Did not resolve the structural mechanism of how binding blocks pore formation","Stoichiometry within an assembling MAC not defined"]},{"year":1992,"claim":"Identified a complement-independent function of CD59 as a CD2 ligand, revealing CD59 as an adhesion and immune-signaling molecule rather than solely a complement regulator.","evidence":"CHO transfection, antibody-blockable rosette assays, radiolabeled CD59 binding to CD2+ cells, and CD2R epitope induction","pmids":["1385156"],"confidence":"High","gaps":["Did not establish downstream signaling consequences","Physiological relevance versus complement role unaddressed"]},{"year":1992,"claim":"Showed CD59 functions in detergent-resistant GPI-anchored membrane complexes containing CD55 and kinase activity, hinting at organized membrane signaling platforms.","evidence":"Co-immunoprecipitation with anti-CD59/anti-CD55 and kinase activity assay of immunoprecipitates from HPB ALL cells","pmids":["1715364"],"confidence":"Medium","gaps":["Kinase not identified","Complex composition not fully characterized","Single Co-IP approach"]},{"year":1992,"claim":"Demonstrated direct costimulatory activity of CD59 in T-cell activation, distinguishing it from a passive adhesion molecule.","evidence":"Single and double CHO transfectants in rosette and T-cell proliferation assays with submitogenic PHA + IL-1","pmids":["1370512"],"confidence":"Medium","gaps":["Mechanism of synergy with CD58 unresolved at this stage","Single lab"]},{"year":1994,"claim":"Defined the molecular requirements for CD59 costimulation, establishing dependence on CD58 co-expression and Asn18 N-glycosylation.","evidence":"CHO transfectants with site-directed Asn18 mutagenesis, proliferation and IL-2 secretion assays with fixed transfectants","pmids":["7521361"],"confidence":"High","gaps":["Did not define the signaling cascade downstream of costimulation","Contrast with glycosylation-independent complement function not reconciled mechanistically"]},{"year":1994,"claim":"Established that the GPI anchor is dispensable for complement inhibition, separating membrane attachment mode from inhibitory function.","evidence":"Retroviral transduction of transmembrane CD59 into GPI-deficient PNH B cells, complement lysis and PI-PLC assays","pmids":["7522635"],"confidence":"Medium","gaps":["GPI-anchored CD59 could not be expressed on GPI-deficient L cells, limiting direct comparison","Spatial positioning requirement not yet defined"]},{"year":1997,"claim":"Confirmed N-glycosylation is not required for complement-inhibitory activity, dissociating the glycan requirement seen in costimulation from the complement role.","evidence":"Asn-16 glycosylation-site mutagenesis of rat CD59 expressed in CHO cells with multi-species complement lysis assays","pmids":["9176120"],"confidence":"High","gaps":["Performed in rat CD59; species generalization not formally tested in human","Effect on non-complement functions not addressed"]},{"year":1999,"claim":"Established that effective complement inhibition requires CD59 positioned in close proximity to MAC assembly sites, defining a spatial constraint on its activity.","evidence":"IgG-CD59 chimeric fusion proteins targeted to antigen-positive CHO cells with complement protection assays","pmids":["9884334"],"confidence":"Medium","gaps":["Quantitative distance/proximity threshold not defined","Bystander protection limits not generalized to native tissue"]},{"year":2001,"claim":"Provided in vivo proof that CD59 is physiologically required to protect erythrocytes from complement, validating the biochemical model in a whole-organism context.","evidence":"CD59-knockout mice with acidified serum lysis test, reticulocyte counts, plasma/urine hemoglobin, and cobra venom factor challenge","pmids":["11435315"],"confidence":"High","gaps":["Did not address non-erythroid or signaling functions in vivo","Compensation by other complement regulators not evaluated"]},{"year":2003,"claim":"Identified CD59 as an NK cell co-receptor physically and functionally coupled to natural cytotoxicity receptors, extending its immune signaling role.","evidence":"Co-IP with NKp46/NKp30, anti-CD59 cytotoxicity assays, and CD3ζ phosphorylation analysis","pmids":["14635045"],"confidence":"High","gaps":["Direct versus indirect association with NCRs not resolved","Endogenous ligand for this co-receptor function unknown"]},{"year":2006,"claim":"Showed CD59-driven NK enhancement requires GPI-anchor-dependent signaling and is glycosylation-independent, mechanistically distinguishing the signaling pathway from membrane raft localization.","evidence":"CD59 anchor variants (GPI, BiMP, transmembrane) in U937 cells, NK cytotoxicity, calcium flux after cross-linking, and lipid raft fractionation","pmids":["16493049"],"confidence":"High","gaps":["Identity of GPI-coupled signaling intermediates not defined","Link to NCR association not mechanistically integrated"]},{"year":2006,"claim":"Identified p53 as a transcriptional regulator of CD59, connecting complement protection to tumor-suppressor and stress signaling.","evidence":"In vitro p53 binding to CD59 promoter elements, siRNA knockdown with CD59 Western blot, and acetylation analysis in HeLa cells","pmids":["16489052"],"confidence":"Medium","gaps":["Direct in vivo promoter occupancy not shown","Physiological context of p53-CD59 axis not established"]},{"year":2006,"claim":"Showed REST represses neuronal CD59, and that relieving this repression protects neurons from complement, linking CD59 regulation to neural cell vulnerability.","evidence":"REST-derived peptide transfection in neuroblastoma and human neurons with CD59 expression and complement lysis assays","pmids":["19884909"],"confidence":"Medium","gaps":["Direct REST binding to CD59 regulatory regions not mapped","Single lab"]},{"year":2006,"claim":"Revealed that CD59 cross-linking actively signals cell death via selective APO2L/TRAIL secretion, recasting CD59 as a death-signaling receptor in T cells.","evidence":"Anti-CD59 cross-linking on Jurkat cells with FasL/TRAIL/APO2L blocking antibodies and confirmation in normal T-cell blasts","pmids":["10760796"],"confidence":"Medium","gaps":["Proximal signaling from CD59 to APO2L secretion not defined","Physiological trigger of cross-linking unknown"]},{"year":2010,"claim":"Demonstrated that CD59-restricted MAC formation protects against vascular pathology, linking complement control to aortic aneurysm and MMP/AP-1/NF-kB signaling.","evidence":"CD59 knockout and human CD59 transgenic mice in angiotensin II aneurysm model with C9, MMP, and AP-1/NF-kB readouts plus in vitro MAC stimulation","pmids":["20212283"],"confidence":"Medium","gaps":["Cell type driving the protective effect not isolated","Whether sublytic MAC versus lysis dominates the phenotype unclear"]},{"year":2014,"claim":"Uncovered an unexpected intracellular role for CD59 in regulated insulin exocytosis through SNARE binding, revealing function beyond the cell surface.","evidence":"Co-IP with VAMP2 and Syntaxin-1, siRNA silencing, TIRF imaging, PI-PLC cleavage, and insulin secretion assays in β-cells","pmids":["24726385"],"confidence":"High","gaps":["Molecular form of intracellular CD59 not yet defined at this stage","Mechanism of SNARE regulation not resolved"]},{"year":2015,"claim":"Defined a Syk-dependent receptor signaling pathway by which CD59 engagement drives erythrocyte necroptosis, mechanistically linking CD59 to programmed cell death.","evidence":"CD59 cross-linking and toxin treatment with Syk inhibition, FasL blocking, and phosphorylation analysis of Band 3, RIP1, RIP3","pmids":["26018734"],"confidence":"Medium","gaps":["Physiological relevance to in vivo hemolysis not established","Coupling of CD59 to Syk activation not defined"]},{"year":2016,"claim":"Defined the structural mechanism by which CD59-dependent cholesterol-dependent cytolysins exploit CD59, including a proline selectivity switch ensuring CD59 binding precedes cholesterol engagement.","evidence":"Crystal structures of VLY:CD59 and ILY:CD59, SAXS, molecular dynamics, and EM/AFM of prepore intermediates","pmids":["27499440","27910935"],"confidence":"High","gaps":["Host benefit or consequence of serving as a toxin receptor not addressed","How CD59 release during pore maturation is triggered structurally not fully defined"]},{"year":2016,"claim":"Identified SOX2 as a CD59 transcriptional activator that shields cancer stem cells from complement, connecting CD59 regulation to tumorigenesis and immune evasion.","evidence":"CD59/SOX2 siRNA silencing, complement lysis assays, and xenograft tumorigenesis in nude mice","pmids":["28017655"],"confidence":"Medium","gaps":["Direct SOX2 binding at the human CD59 locus not fully mapped","Cancer-type generality not established"]},{"year":2018,"claim":"Systematically characterized all known congenital CD59 mutations, showing they all yield nonfunctional protein that fails to inhibit MAC despite varied surface trafficking and antibody recognition.","evidence":"Expression of four mutants with myc-tag and anti-CD59 labeling, glycosylation Western blots, secretion analysis, and complement lysis assays","pmids":["30533526"],"confidence":"Medium","gaps":["Structural basis for antibody non-recognition of surface-reaching mutants not solved","Genotype-phenotype variability not explained"]},{"year":2018,"claim":"Linked CD59 deficiency to radioresistance via Src kinase signaling and impaired DNA damage repair, indicating CD59 influences intracellular stress responses in cancer.","evidence":"CD59 knockdown/overexpression in ESCC cells with gamma-H2AX, cell cycle, senescence, phospho-Src Y416 analysis, and Src inhibitor treatment","pmids":["30166523"],"confidence":"Medium","gaps":["Direct molecular link between CD59 and Src activation not defined","Surface versus intracellular CD59 contribution not distinguished"]},{"year":2021,"claim":"Placed CD59 within the LecA-Gb3 lipid raft domain co-opted for P. aeruginosa invasion, implicating CD59-containing membrane domains in host-pathogen entry.","evidence":"LecA pulldown with mass spectrometry and CD59 depletion bacterial invasion assays","pmids":["33555391"],"confidence":"Medium","gaps":["Whether CD59 is functionally required or a bystander raft constituent not fully resolved","Direct CD59-LecA interaction not demonstrated"]},{"year":2022,"claim":"Resolved the molecular identity of intracellular insulin-regulating CD59 as alternatively spliced non-GPI cytosolic isoforms (IRIS-1/2) that bind SNAREs and are required for secretion, completing the mechanistic picture of CD59 in β-cell exocytosis.","evidence":"Splice-variant cloning, Co-IP with VAMP2/SNAP25, insulin-granule colocalization, CD59-KO rescue, and CRISPR knockout of mouse intracellular isoforms","pmids":["35666870"],"confidence":"High","gaps":["Precise step in SNARE assembly modulated by IRIS isoforms not defined","Relevance to human diabetes not established"]},{"year":2023,"claim":"Provided the high-resolution structural mechanism of MAC inhibition, showing CD59 forms an intermolecular beta-sheet with C8 hairpins and deflects C9 hairpins to halt polymerization.","evidence":"Cryo-EM of C5b8:CD59 and C5b9:CD59 with cellular lysis assays and molecular dynamics simulations","pmids":["36797260"],"confidence":"High","gaps":["Stoichiometry of CD59 needed per MAC in vivo not addressed","Kinetics of CD59 capture during rapid assembly not resolved"]},{"year":null,"claim":"How CD59's distinct activities — surface complement inhibition, GPI-coupled co-receptor signaling, death-pathway triggering, and intracellular SNARE-mediated exocytosis — are coordinated and physiologically prioritized within and across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking GPI-anchored signaling to defined intracellular effectors","Regulation of splice-isoform choice between canonical CD59 and IRIS isoforms not characterized","Relative in vivo contribution of complement-dependent versus complement-independent functions not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,27]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[3,5]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,11]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[18,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,26]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,9]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,20]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[8,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12,20]}],"complexes":["MAC (C5b-9) inhibitory complex","lipid raft / GPI-anchored signaling complex"],"partners":["C8","C9","CD2","CD58","NKP46","NKP30","VAMP2","STX1A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13987","full_name":"CD59 glycoprotein","aliases":["1F5 antigen","20 kDa homologous restriction factor","HRF-20","HRF20","MAC-inhibitory protein","MAC-IP","MEM43 antigen","Membrane attack complex inhibition factor","MACIF","Membrane inhibitor of reactive lysis","MIRL","Protectin"],"length_aa":128,"mass_kda":14.2,"function":"Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation (PubMed:11882685, PubMed:1698710, PubMed:2475111, PubMed:2475570, PubMed:2606909, PubMed:9053451). Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore (PubMed:11882685, PubMed:1698710, PubMed:36797260) The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit complement membrane attack complex (MAC) assembly on cell membranes","subcellular_location":"Cell membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/P13987/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD59","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD59","total_profiled":1310},"omim":[{"mim_id":"621398","title":"CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 100; CFAP100","url":"https://www.omim.org/entry/621398"},{"mim_id":"620781","title":"TRANSMEMBRANE PROTEIN 208; TMEM208","url":"https://www.omim.org/entry/620781"},{"mim_id":"619985","title":"GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 25; GPIBD25","url":"https://www.omim.org/entry/619985"},{"mim_id":"619979","title":"CHROMOSOME 18 OPEN READING FRAME 32; C18ORF32","url":"https://www.omim.org/entry/619979"},{"mim_id":"619812","title":"BLOOD GROUP, EMM SYSTEM; EMM","url":"https://www.omim.org/entry/619812"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Golgi apparatus","reliability":"Uncertain"},{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CD59"},"hgnc":{"alias_symbol":["16.3A5","EJ16","EJ30","EL32","G344","p18-20"],"prev_symbol":["MIC11","MIN1","MSK21","MIN2","MIN3","MIRL","MACIF","HRF20"]},"alphafold":{"accession":"P13987","domains":[{"cath_id":"2.10.60.10","chopping":"24-118","consensus_level":"high","plddt":84.6687,"start":24,"end":118}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13987","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13987-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13987-F1-predicted_aligned_error_v6.png","plddt_mean":79.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD59","jax_strain_url":"https://www.jax.org/strain/search?query=CD59"},"sequence":{"accession":"P13987","fasta_url":"https://rest.uniprot.org/uniprotkb/P13987.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13987/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13987"}},"corpus_meta":[{"pmid":"12645951","id":"PMC_12645951","title":"Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12645951","citation_count":287,"is_preprint":false},{"pmid":"11394505","id":"PMC_11394505","title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.","date":"2001","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/11394505","citation_count":165,"is_preprint":false},{"pmid":"11435315","id":"PMC_11435315","title":"Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11435315","citation_count":116,"is_preprint":false},{"pmid":"23149847","id":"PMC_23149847","title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23149847","citation_count":114,"is_preprint":false},{"pmid":"16884774","id":"PMC_16884774","title":"Alternative roles for CD59.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16884774","citation_count":110,"is_preprint":false},{"pmid":"1377690","id":"PMC_1377690","title":"The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the \"b\"domain of C9.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1377690","citation_count":105,"is_preprint":false},{"pmid":"11027207","id":"PMC_11027207","title":"Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11027207","citation_count":104,"is_preprint":false},{"pmid":"1385156","id":"PMC_1385156","title":"CD59 molecule: a second ligand for CD2 in T cell adhesion.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1385156","citation_count":98,"is_preprint":false},{"pmid":"23474221","id":"PMC_23474221","title":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.","date":"2013","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23474221","citation_count":92,"is_preprint":false},{"pmid":"17289551","id":"PMC_17289551","title":"The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.","date":"2006","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17289551","citation_count":84,"is_preprint":false},{"pmid":"1370512","id":"PMC_1370512","title":"CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1370512","citation_count":83,"is_preprint":false},{"pmid":"1715364","id":"PMC_1715364","title":"Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1715364","citation_count":76,"is_preprint":false},{"pmid":"16289746","id":"PMC_16289746","title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.","date":"2005","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16289746","citation_count":76,"is_preprint":false},{"pmid":"14635045","id":"PMC_14635045","title":"CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14635045","citation_count":74,"is_preprint":false},{"pmid":"10931136","id":"PMC_10931136","title":"Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10931136","citation_count":71,"is_preprint":false},{"pmid":"36271172","id":"PMC_36271172","title":"Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.","date":"2022","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36271172","citation_count":70,"is_preprint":false},{"pmid":"7531640","id":"PMC_7531640","title":"Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family.","date":"1995","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7531640","citation_count":69,"is_preprint":false},{"pmid":"8667608","id":"PMC_8667608","title":"Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.","date":"1996","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8667608","citation_count":69,"is_preprint":false},{"pmid":"24726385","id":"PMC_24726385","title":"The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.","date":"2014","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24726385","citation_count":64,"is_preprint":false},{"pmid":"7530684","id":"PMC_7530684","title":"The expression of CD59 in normal human nervous tissue.","date":"1994","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7530684","citation_count":63,"is_preprint":false},{"pmid":"36797260","id":"PMC_36797260","title":"Structural basis for membrane attack complex inhibition by CD59.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36797260","citation_count":60,"is_preprint":false},{"pmid":"10946279","id":"PMC_10946279","title":"Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10946279","citation_count":59,"is_preprint":false},{"pmid":"7513011","id":"PMC_7513011","title":"Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7513011","citation_count":58,"is_preprint":false},{"pmid":"9185710","id":"PMC_9185710","title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9185710","citation_count":57,"is_preprint":false},{"pmid":"15167611","id":"PMC_15167611","title":"Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination.","date":"2004","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/15167611","citation_count":56,"is_preprint":false},{"pmid":"24915776","id":"PMC_24915776","title":"The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.","date":"2014","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/24915776","citation_count":56,"is_preprint":false},{"pmid":"15693845","id":"PMC_15693845","title":"Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor.","date":"2005","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/15693845","citation_count":56,"is_preprint":false},{"pmid":"28928834","id":"PMC_28928834","title":"CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28928834","citation_count":54,"is_preprint":false},{"pmid":"20212283","id":"PMC_20212283","title":"Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20212283","citation_count":54,"is_preprint":false},{"pmid":"22541656","id":"PMC_22541656","title":"Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration.","date":"2012","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/22541656","citation_count":51,"is_preprint":false},{"pmid":"1281489","id":"PMC_1281489","title":"Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.","date":"1992","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/1281489","citation_count":50,"is_preprint":false},{"pmid":"7517877","id":"PMC_7517877","title":"Expression and function of CD59 on colonic adenocarcinoma cells.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7517877","citation_count":50,"is_preprint":false},{"pmid":"29521526","id":"PMC_29521526","title":"CD59: a promising target for tumor immunotherapy.","date":"2018","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29521526","citation_count":48,"is_preprint":false},{"pmid":"1372164","id":"PMC_1372164","title":"Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1372164","citation_count":48,"is_preprint":false},{"pmid":"10375708","id":"PMC_10375708","title":"Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10375708","citation_count":46,"is_preprint":false},{"pmid":"9664126","id":"PMC_9664126","title":"Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).","date":"1998","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9664126","citation_count":44,"is_preprint":false},{"pmid":"7538183","id":"PMC_7538183","title":"Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis.","date":"1995","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7538183","citation_count":42,"is_preprint":false},{"pmid":"17080916","id":"PMC_17080916","title":"Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia.","date":"2006","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/17080916","citation_count":41,"is_preprint":false},{"pmid":"12880676","id":"PMC_12880676","title":"Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12880676","citation_count":41,"is_preprint":false},{"pmid":"1383553","id":"PMC_1383553","title":"Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation.","date":"1992","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1383553","citation_count":41,"is_preprint":false},{"pmid":"28922377","id":"PMC_28922377","title":"C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis.","date":"2017","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/28922377","citation_count":40,"is_preprint":false},{"pmid":"24978917","id":"PMC_24978917","title":"Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.","date":"2014","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24978917","citation_count":39,"is_preprint":false},{"pmid":"28500075","id":"PMC_28500075","title":"Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28500075","citation_count":39,"is_preprint":false},{"pmid":"14712499","id":"PMC_14712499","title":"Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14712499","citation_count":38,"is_preprint":false},{"pmid":"30166523","id":"PMC_30166523","title":"CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30166523","citation_count":37,"is_preprint":false},{"pmid":"10086790","id":"PMC_10086790","title":"CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia.","date":"1999","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10086790","citation_count":37,"is_preprint":false},{"pmid":"9884334","id":"PMC_9884334","title":"Targeting of functional antibody-CD59 fusion proteins to a cell surface.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9884334","citation_count":36,"is_preprint":false},{"pmid":"20727519","id":"PMC_20727519","title":"Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients.","date":"2010","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20727519","citation_count":35,"is_preprint":false},{"pmid":"7691609","id":"PMC_7691609","title":"Regulation of CD59 expression on the human endothelial cell line EA.hy 926.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7691609","citation_count":35,"is_preprint":false},{"pmid":"10680700","id":"PMC_10680700","title":"Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.","date":"2000","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10680700","citation_count":34,"is_preprint":false},{"pmid":"25716358","id":"PMC_25716358","title":"Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25716358","citation_count":34,"is_preprint":false},{"pmid":"28476558","id":"PMC_28476558","title":"Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28476558","citation_count":33,"is_preprint":false},{"pmid":"7521361","id":"PMC_7521361","title":"CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7521361","citation_count":33,"is_preprint":false},{"pmid":"28017655","id":"PMC_28017655","title":"CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.","date":"2016","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28017655","citation_count":33,"is_preprint":false},{"pmid":"27159394","id":"PMC_27159394","title":"Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27159394","citation_count":32,"is_preprint":false},{"pmid":"23835643","id":"PMC_23835643","title":"CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23835643","citation_count":31,"is_preprint":false},{"pmid":"7694573","id":"PMC_7694573","title":"Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.","date":"1993","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7694573","citation_count":31,"is_preprint":false},{"pmid":"27499440","id":"PMC_27499440","title":"Structural Basis for Receptor Recognition by the Human CD59-Responsive Cholesterol-Dependent Cytolysins.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27499440","citation_count":31,"is_preprint":false},{"pmid":"16271846","id":"PMC_16271846","title":"Effects of CD59 on antitumoral activities of phycocyanin from Spirulina platensis.","date":"2005","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16271846","citation_count":30,"is_preprint":false},{"pmid":"32185543","id":"PMC_32185543","title":"CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells.","date":"2020","source":"AMB Express","url":"https://pubmed.ncbi.nlm.nih.gov/32185543","citation_count":30,"is_preprint":false},{"pmid":"7691713","id":"PMC_7691713","title":"Colocalization of the human CD59 gene to 11p13 with the MIC11 cell surface antigen.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7691713","citation_count":29,"is_preprint":false},{"pmid":"1379443","id":"PMC_1379443","title":"CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex.","date":"1992","source":"Experimental and clinical immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/1379443","citation_count":28,"is_preprint":false},{"pmid":"12751952","id":"PMC_12751952","title":"Computerized video time-lapse (CVTL) analysis of the fate of giant cells produced by X-irradiating EJ30 human bladder carcinoma cells.","date":"2003","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/12751952","citation_count":28,"is_preprint":false},{"pmid":"19254481","id":"PMC_19254481","title":"CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer.","date":"2009","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19254481","citation_count":27,"is_preprint":false},{"pmid":"16876248","id":"PMC_16876248","title":"Cloning of a CD59-like gene in rainbow trout. Expression and phylogenetic analysis of two isoforms.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16876248","citation_count":27,"is_preprint":false},{"pmid":"8807596","id":"PMC_8807596","title":"Transfected CD59 protects mesangial cells from injury induced by antibody and complement.","date":"1996","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/8807596","citation_count":27,"is_preprint":false},{"pmid":"16968237","id":"PMC_16968237","title":"Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.","date":"2006","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16968237","citation_count":27,"is_preprint":false},{"pmid":"29447841","id":"PMC_29447841","title":"CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.","date":"2018","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/29447841","citation_count":26,"is_preprint":false},{"pmid":"10760796","id":"PMC_10760796","title":"CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10760796","citation_count":26,"is_preprint":false},{"pmid":"9176120","id":"PMC_9176120","title":"Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.","date":"1997","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9176120","citation_count":26,"is_preprint":false},{"pmid":"17234541","id":"PMC_17234541","title":"Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.","date":"2006","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/17234541","citation_count":26,"is_preprint":false},{"pmid":"22000275","id":"PMC_22000275","title":"The effects of CD59 gene as a target gene on breast cancer cells.","date":"2011","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22000275","citation_count":25,"is_preprint":false},{"pmid":"35666870","id":"PMC_35666870","title":"Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35666870","citation_count":25,"is_preprint":false},{"pmid":"33555391","id":"PMC_33555391","title":"The Gb3-enriched CD59/flotillin plasma membrane domain regulates host cell invasion by Pseudomonas aeruginosa.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33555391","citation_count":25,"is_preprint":false},{"pmid":"24205416","id":"PMC_24205416","title":"On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.","date":"2013","source":"PLoS neglected tropical diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24205416","citation_count":25,"is_preprint":false},{"pmid":"19884909","id":"PMC_19884909","title":"Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19884909","citation_count":25,"is_preprint":false},{"pmid":"31739586","id":"PMC_31739586","title":"Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection.","date":"2019","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/31739586","citation_count":24,"is_preprint":false},{"pmid":"26018734","id":"PMC_26018734","title":"CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/26018734","citation_count":24,"is_preprint":false},{"pmid":"16493049","id":"PMC_16493049","title":"Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16493049","citation_count":24,"is_preprint":false},{"pmid":"21464923","id":"PMC_21464923","title":"Gecko CD59 is implicated in proximodistal identity during tail regeneration.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21464923","citation_count":24,"is_preprint":false},{"pmid":"16489052","id":"PMC_16489052","title":"p53 regulates cellular resistance to complement lysis through enhanced expression of CD59.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16489052","citation_count":24,"is_preprint":false},{"pmid":"27910935","id":"PMC_27910935","title":"Disentangling the roles of cholesterol and CD59 in intermedilysin pore formation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27910935","citation_count":23,"is_preprint":false},{"pmid":"10667419","id":"PMC_10667419","title":"Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease.","date":"1999","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10667419","citation_count":23,"is_preprint":false},{"pmid":"18632654","id":"PMC_18632654","title":"Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18632654","citation_count":22,"is_preprint":false},{"pmid":"11395643","id":"PMC_11395643","title":"Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.","date":"2001","source":"Journal of immunotherapy : official journal of the Society for Biological Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11395643","citation_count":22,"is_preprint":false},{"pmid":"24616098","id":"PMC_24616098","title":"Rapid degradation of the complement regulator, CD59, by a novel inhibitor.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24616098","citation_count":21,"is_preprint":false},{"pmid":"12452769","id":"PMC_12452769","title":"Computerized video time-lapse (CVTL) analysis of cell death kinetics in human bladder carcinoma cells (EJ30) X-irradiated in different phases of the cell cycle.","date":"2002","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/12452769","citation_count":20,"is_preprint":false},{"pmid":"18443552","id":"PMC_18443552","title":"Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection.","date":"2008","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/18443552","citation_count":20,"is_preprint":false},{"pmid":"23707788","id":"PMC_23707788","title":"Zebrafish CD59 has both bacterial-binding and inhibiting activities.","date":"2013","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23707788","citation_count":20,"is_preprint":false},{"pmid":"7522635","id":"PMC_7522635","title":"Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7522635","citation_count":20,"is_preprint":false},{"pmid":"28622911","id":"PMC_28622911","title":"Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28622911","citation_count":19,"is_preprint":false},{"pmid":"25725314","id":"PMC_25725314","title":"Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25725314","citation_count":19,"is_preprint":false},{"pmid":"10972227","id":"PMC_10972227","title":"Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells.","date":"2000","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/10972227","citation_count":19,"is_preprint":false},{"pmid":"7687899","id":"PMC_7687899","title":"Enhanced expression of the complement regulatory protein, membrane inhibitor of reactive lysis (CD59), is regulated at the level of transcription.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7687899","citation_count":18,"is_preprint":false},{"pmid":"23109726","id":"PMC_23109726","title":"Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23109726","citation_count":18,"is_preprint":false},{"pmid":"30533526","id":"PMC_30533526","title":"Molecular pathogenesis of human CD59 deficiency.","date":"2018","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30533526","citation_count":17,"is_preprint":false},{"pmid":"11920231","id":"PMC_11920231","title":"Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.","date":"2001","source":"The hematology journal : the official journal of the European Haematology Association","url":"https://pubmed.ncbi.nlm.nih.gov/11920231","citation_count":17,"is_preprint":false},{"pmid":"12086907","id":"PMC_12086907","title":"Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.","date":"2001","source":"Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","url":"https://pubmed.ncbi.nlm.nih.gov/12086907","citation_count":17,"is_preprint":false},{"pmid":"25818314","id":"PMC_25818314","title":"Paroxysmal nocturnal hemoglobinuria (PNH) and primary p.Cys89Tyr mutation in CD59: Differences and similarities.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25818314","citation_count":16,"is_preprint":false},{"pmid":"21953001","id":"PMC_21953001","title":"Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis.","date":"2011","source":"Revista brasileira de reumatologia","url":"https://pubmed.ncbi.nlm.nih.gov/21953001","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48515,"output_tokens":7606,"usd":0.129818,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17136,"output_tokens":7010,"usd":0.130465,"stage2_stop_reason":"end_turn"},"total_usd":0.260283,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 binds specifically to the alpha-chain of C8 and to the C9b domain (37-kDa fragment) of C9, but not to C8 beta, C8 gamma, C9a, C5b6, or C7, establishing that CD59 inhibits MAC assembly through direct protein-protein interactions with these specific complement components.\",\n      \"method\": \"Radiolabeled (125I) CD59 binding assays to surface-adsorbed complement proteins, ligand blotting after SDS-PAGE separation of C8 subunits, and thrombin digestion of C9; saturable binding with defined Kd values\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution binding assay with radiolabeled ligand, subunit dissection, proteolytic mapping, and saturable kinetics; single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"1377690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of inhibited MAC precursors C5b8 and C5b9 reveal that CD59 binds the pore-forming β-hairpins of C8 to form an intermolecular β-sheet that prevents membrane perforation; while bound to C8, CD59 deflects cascading C9 β-hairpins into the membrane rather than allowing polymerization, thereby restricting structural transitions of subsequent C9 monomers and indirectly halting MAC polymerization.\",\n      \"method\": \"Cryo-electron microscopy structures of C5b8:CD59 and C5b9:CD59 complexes, combined with cellular complement lysis assays and molecular dynamics simulations\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structures with multiple complexes, validated by cellular assays and MD simulations in one study\",\n      \"pmids\": [\"36797260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Targeted gene deletion of CD59 in mice causes spontaneous intravascular hemolysis: CD59-deficient erythrocytes show increased susceptibility to complement in vitro, and mice have elevated reticulocyte counts plus hemoglobin in plasma and urine, demonstrating that CD59 is required in vivo to protect erythrocytes from MAC-mediated lysis.\",\n      \"method\": \"Gene targeting in embryonic stem cells to generate CD59-knockout mice; in vitro acidified serum lysis test; reticulocyte counts; plasma and urine hemoglobin measurements; cobra venom factor challenge\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple orthogonal phenotypic readouts (lysis assay, reticulocyte counts, hemoglobin measurements), replicated across conditions\",\n      \"pmids\": [\"11435315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 functions as a second ligand for the T cell surface molecule CD2: CHO cells expressing human CD59 form rosettes with human T cells inhibitable by anti-CD59 and anti-CD2 antibodies; radiolabeled CD59 binds specifically to CD2-expressing cells; and CD59 binding to T cells induces expression of CD2R epitopes, indicating a direct CD59–CD2 adhesion interaction.\",\n      \"method\": \"CHO cell transfection with CD59 cDNA; rosette assay with antibody blocking; 125I-labeled CD59 binding to CD2+ transfectants; CD2R epitope induction assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional assays (rosette inhibition, radiolabeled ligand binding, epitope induction) in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"1385156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 is physically associated in a detergent-resistant complex with an 80-kDa glycoprotein, CD55, and glycolipids on HPB ALL cells; the complex also contains protein kinase activity, suggesting CD59 participates in GPI-anchored membrane signaling complexes.\",\n      \"method\": \"Co-immunoprecipitation from detergent lysates with anti-CD59 and anti-CD55 mAbs; SDS-PAGE analysis; protein kinase activity assay of immunoprecipitates\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP approach with kinase activity follow-up in one lab; complex not fully characterized\",\n      \"pmids\": [\"1715364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 and CD58 exhibit additive/synergistic roles in T cell adhesion and activation: CD59-expressing CHO transfectants alone induce T cell rosettes and sevenfold proliferation enhancement, while double CD58+CD59 transfectants produce >40-fold enhancement—far exceeding the sum of single transfectants—demonstrating direct costimulatory function of CD59.\",\n      \"method\": \"Stable CHO cell transfectants expressing CD59, CD58, or both; rosette assay; T cell proliferation assay with submitogenic PHA + IL-1\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean transfection system with two functional readouts (adhesion, proliferation), single lab\",\n      \"pmids\": [\"1370512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD59 costimulation of T cell activation requires CD58 co-expression and N-glycosylation at Asn18: CD59 enhanced CD58-dependent proliferation and IL-2 secretion, but a glycosylation-deficient CD59 (mutated at Asn18) abolished this costimulatory activity, while CD59 alone without CD58 could not support proliferation.\",\n      \"method\": \"CHO transfectants expressing rCD58, rCD59, or both; site-directed mutagenesis of N-glycosylation site Asn18; T cell proliferation and IL-2 secretion assays with paraformaldehyde-fixed transfectants\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with functional reconstitution assays establishing glycosylation requirement; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"7521361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD59 functions as a co-receptor in human NK cell activation: CD59 is physically associated with NKp46 and NKp30 (natural cytotoxicity receptors), and antibody engagement of CD59 enhances NK cytotoxicity in an NKp46-dependent manner, triggering tyrosine phosphorylation of CD3ζ chains associated with NKp46 and NKp30 but not CD16.\",\n      \"method\": \"Co-immunoprecipitation of CD59 with NCRs; NK cytotoxicity assays with anti-CD59 mAb; NKp46 modulation experiments; biochemical phosphorylation analysis of CD3ζ chains\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, functional cytotoxicity assays, and signaling analysis (ζ-chain phosphorylation) in one study with multiple orthogonal methods\",\n      \"pmids\": [\"14635045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD59 regulates insulin secretion through intracellular interactions with exocytotic SNARE proteins VAMP2 and Syntaxin-1: most CD59 in pancreatic β-cells is intracellular; silencing intracellular CD59 markedly suppresses regulated exocytosis, while removing extracellular CD59 only moderately stimulates secretion; CD59 co-immunoprecipitates with VAMP2 and Syntaxin-1.\",\n      \"method\": \"Co-immunoprecipitation of CD59 with VAMP2 and Syntaxin-1; siRNA silencing of CD59; TIRF microscopy imaging of exocytosis; PI-PLC cleavage to remove extracellular CD59; insulin secretion assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of binding partners, TIRF live-cell imaging, and loss-of-function assays in one study with multiple orthogonal methods\",\n      \"pmids\": [\"24726385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Alternative splicing of the CD59 gene produces non-GPI-anchored cytosolic isoforms (IRIS-1 and IRIS-2) in human pancreatic β-cells that interact with SNARE proteins VAMP2 and SNAP25, colocalize with insulin granules, and rescue insulin secretion in CD59-knockout cells; CRISPR/Cas9 knockout of the mouse intracellular isoforms (not canonical CD59B) specifically abrogates insulin secretion.\",\n      \"method\": \"RT-PCR and sequencing of CD59 splice variants; co-immunoprecipitation with VAMP2 and SNAP25; confocal colocalization with insulin granules; CD59-KO cell rescue experiments; CRISPR/Cas9 knockout of mouse isoforms; insulin secretion assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — molecular cloning, Co-IP, CRISPR knockout with rescue, and functional secretion assays; multiple orthogonal methods in one study\",\n      \"pmids\": [\"35666870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"N-glycosylation of rat CD59 is not required for complement-inhibitory function: a point-mutant lacking the N-glycosylation site at Asn-16 (reducing MW from ~20-28 kDa to ~12 kDa) retains at least as potent complement-inhibitory activity as the wild-type molecule.\",\n      \"method\": \"Site-directed mutagenesis of N-glycosylation site; expression in CHO cells; complement lysis assay with multiple species' sera; antibody blocking confirmation\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional reconstitution in CHO cells, antibody-blocking controls; single lab with clean mechanistic result\",\n      \"pmids\": [\"9176120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD59-mediated NK cell activation and enhanced target cell susceptibility to NK killing requires GPI anchor-dependent signaling: GPI-anchored CD59 (by transfection or membrane incorporation) increases NK cytotoxicity against target cells, whereas CD59 anchored via a bis-myristoylated peptide or a transmembrane domain does not, despite similar lipid raft localization; unglycosylated GPI-anchored CD59 retains this activity, confirming GPI anchor dependence and glycosylation independence.\",\n      \"method\": \"CD59 transfection and membrane incorporation with different anchor types (GPI, BiMP, transmembrane) in U937 cells; NK cytotoxicity assays; calcium flux assays after CD59 cross-linking; lipid raft fractionation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple anchor variants tested functionally, calcium signaling readout, lipid raft analysis; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"16493049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cross-linking of CD59 on Jurkat T cells induces cell death via preferential secretion of APO2L/TRAIL (not FasL or TRAIL), distinct from TCR-mediated AICD which uses both FasL and TRAIL; this was confirmed in normal human T cell blasts where anti-CD59 cross-linking supernatants were toxic in a manner fully blocked by anti-APO2L antibody.\",\n      \"method\": \"Anti-CD59 antibody cross-linking on Jurkat and J.RT3.T3.5 cells; blocking antibodies against FasL, TRAIL, and anti-APO2L; cytotoxicity assays on supernatants; normal T cell blasts confirmation\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cross-linking with defined blocking antibodies establishing TRAIL specificity; single lab\",\n      \"pmids\": [\"10760796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CD59 expression on endothelial cells is upregulated at the transcriptional level by PKC activators (PMA) and PKA activators (db-cAMP), with functional consequence of increased resistance to complement-mediated lysis; Northern blot showed increases in CD59 mRNA (particularly 1.9, 2.1, and 5.8 kb transcripts).\",\n      \"method\": \"PKC and PKA agonist treatment of EA.hy 926 endothelial cells; flow cytometry of surface CD59; Northern blot analysis; complement lysis assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — expression regulation with functional lysis assay follow-up; multiple agonists tested in one lab\",\n      \"pmids\": [\"7691609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Enhanced CD59 (MIRL) expression in response to PMA is regulated at the level of transcription and requires de novo protein synthesis: PMA-induced CD59 RNA upregulation was abrogated by both a protein synthesis inhibitor and a transcription inhibitor, consistent with induction of a trans-acting factor that promotes CD59 transcription.\",\n      \"method\": \"PMA stimulation of K562 cells; Northern blot for CD59 RNA; immunoprecipitation and Western blot for CD59 protein; cycloheximide (protein synthesis inhibitor) and actinomycin D (transcription inhibitor) experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcription and translation inhibitor experiments with mRNA and protein readouts; single lab\",\n      \"pmids\": [\"7687899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD59 expression is regulated by p53: p53 binds two putative p53-responsive elements in the CD59 gene in vitro; p53 knockdown by siRNA reduces CD59 protein expression sixfold in HeLa cells; acetylation status of p53 modulates CD59 expression in cells exposed to inflammatory cytokines.\",\n      \"method\": \"In vitro p53 binding to CD59 gene p53-responsive elements; siRNA knockdown of p53; Western blot of CD59 protein; acetylation status analysis; camptothecin-induced apoptosis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro DNA binding plus siRNA knockdown with protein readout; single lab\",\n      \"pmids\": [\"16489052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD59 expression in neurons is regulated by the neural-restrictive silencer factor (REST), which represses CD59 transcription; a REST-derived peptide (REST5) containing the nuclear localization domain upregulates CD59 expression fivefold in neurons and protects them from complement-mediated lysis.\",\n      \"method\": \"REST peptide transfection in neuroblastoma cells and human neurons differentiated from neural progenitor cells; CD59 expression measurements; complement lysis assays with human serum or oligodendroglia-conditioned medium\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic REST peptide intervention with expression and functional readouts; single lab\",\n      \"pmids\": [\"19884909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SOX2 transcription factor upregulates CD59 expression in epithelial cancer stem cells to protect them from complement-dependent cytotoxicity; CD59 silencing in cancer stem cells enhanced complement-mediated destruction and suppressed tumorigenesis in xenograft models; SOX2 also regulates mCd59b transcription in murine testis spermatogonial stem cells.\",\n      \"method\": \"CD59 and SOX2 siRNA silencing; sphere-forming cancer stem cell preparation; complement lysis assays; xenograft tumorigenesis in nude mice; SOX2-CD59 transcriptional regulation analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with in vivo xenograft confirmation and transcriptional regulation data; single lab\",\n      \"pmids\": [\"28017655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Intermedilysin (ILY) binds CD59 to coordinate monomer assembly and trigger collapse of an oligomeric prepore: CD59 is required for specific coordination of ILY monomers; movement of ILY Domain 2 relative to Domain 3 forms a late prepore intermediate that releases CD59, while cholesterol mediates transmembrane segment insertion.\",\n      \"method\": \"Biochemical binding assays; electron microscopy; atomic force microscopy of ILY pore formation intermediates\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EM and AFM structural analysis combined with biochemical assays defining stepwise mechanism; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27910935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of vaginolysin and intermedilysin (CD59-responsive cholesterol-dependent cytolysins) complexed with CD59 show that each toxin binds CD59 at different but overlapping sites; the proline substitution in the CDC undecapeptide consensus motif acts as a selectivity switch ensuring CD59-dependent CDCs bind CD59 before cholesterol.\",\n      \"method\": \"X-ray crystal structures of VLY:CD59 and ILY:CD59 complexes; small-angle X-ray scattering; molecular dynamics simulations; binding studies\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — two independent crystal structures validated by SAXS and MD simulations; single study, multiple orthogonal methods\",\n      \"pmids\": [\"27499440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD59 receptor signaling drives Syk-dependent erythrocyte necroptosis: binding or crosslinking of CD59 leads to Syk-dependent echinocyte formation with Band 3 phosphorylation and FasL release; FasL-dependent phosphorylation of RIP1, combined with membrane pore formation, triggers RIP3 phosphorylation and necroptosis execution.\",\n      \"method\": \"CD59 antibody crosslinking; human CD59-targeted pore-forming toxin treatment; Syk inhibition; FasL blocking antibody; phosphorylation analysis of Band 3, RIP1, RIP3; cell death assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — signaling pathway dissection with specific inhibitors and phosphorylation readouts; single lab\",\n      \"pmids\": [\"26018734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD59 protects against abdominal aortic aneurysm development: CD59-deficient mice develop more severe angiotensin II-induced aneurysms with increased C9 deposition, MMP2/9 activity, and phosphorylated AP-1/NF-κB components; transgenic human CD59 overexpression attenuates aneurysm progression; MAC directly induces MMP-2 and MMP-9 gene expression in vitro through AP-1 and NF-κB pathways.\",\n      \"method\": \"CD59 knockout and human CD59 transgenic mice in ApoE-null angiotensin II aneurysm model; C9 deposition measurement; MMP2/9 activity assays; phosphorylation of AP-1/NF-κB components; in vitro MAC stimulation of gene expression\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary KO and transgenic overexpression with defined downstream signaling readouts; single lab\",\n      \"pmids\": [\"20212283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD59 is an integral component of the LecA-Gb3 lipid raft membrane domain in P. aeruginosa invasion: flotillins and CD59 co-purify with the LecA-interacting domain by pulldown and mass spectrometry; depletion of CD59 reduces PAO1 bacterial invasiveness by ~50%.\",\n      \"method\": \"Pulldown and mass spectrometry of LecA-associated membrane domain; CD59 depletion; bacterial invasion assay measuring P. aeruginosa PAO1 uptake\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry identification plus functional depletion assay; single lab\",\n      \"pmids\": [\"33555391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Transmembrane-anchored recombinant CD59 expressed on GPI-anchoring deficient PNH B cells confers resistance to complement-mediated lysis, demonstrating that GPI anchoring is not strictly required for CD59 complement-inhibitory function; however, GPI-anchored CD59 cannot be expressed on GPI-deficient L cells while transmembrane CD59 can.\",\n      \"method\": \"Retroviral transduction of transmembrane CD59 (CD59-TM) construct into GPI-deficient PNH B cells and mouse L cells; complement lysis assay with human serum; PI-PLC treatment to confirm membrane anchor type; flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution in disease-relevant PNH cells with complement lysis assay; single lab\",\n      \"pmids\": [\"7522635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 gene has a structure of one 5'-untranslated exon and three coding exons spanning >27 kb, and produces multiple mRNA isoforms (>4) through alternative polyadenylation at distinct sites in the 3' region.\",\n      \"method\": \"Genomic library cloning; Southern blotting; Northern blot with six different 3'-region probes; RACE (rapid amplification of cDNA ends)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic cloning and multiple Northern probes establishing gene structure and polyadenylation; single lab\",\n      \"pmids\": [\"1383553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD59 deficiency promotes radioresistance of esophageal cancer cells through Src kinase activation: CD59 deficiency exacerbates DNA damage, impairs DNA damage repair, induces G2/M arrest and senescence, and reduces Src phosphorylation at Y416 after ionizing radiation; pharmacological Src inhibition sensitizes cells to radiation.\",\n      \"method\": \"CD59 knockdown/overexpression in ESCC cell lines; irradiation; DNA damage assays (γ-H2AX); cell cycle analysis; senescence assay; Western blot for phospho-Src Y416; Src inhibitor saracatinib treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with mechanistic Src signaling readout and pharmacological validation; single lab\",\n      \"pmids\": [\"30166523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A homozygous p.Cys89Tyr missense mutation in CD59 causes failure of proper CD59 localization to the cell surface membrane, resulting in congenital chronic hemolysis and relapsing peripheral demyelinating polyneuropathy; mutant protein is present intracellularly but undetectable on the membrane surface by flow cytometry and Western blot.\",\n      \"method\": \"Homozygosity mapping, exome sequencing, Sanger sequencing; flow cytometry for CD59/CD55/CD14 surface expression; Western blot of CD59 protein\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mapping with protein localization analysis; single study\",\n      \"pmids\": [\"23149847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"All four known CD59 congenital mutations generate nonfunctional CD59 that fails to inhibit MAC formation; two missense mutants (p.Cys64Tyr and p.Asp24Val) reach the cell surface but are not recognized by known anti-CD59 antibodies; two frameshift mutants remain intracellular; all mutants show normal glycosylation but mutant-specific secretion patterns.\",\n      \"method\": \"Cloning and expression of all four mutants in plasmids; myc-tag immunolabeling; anti-CD59 antibody labeling; Western blot for glycosylation; complement lysis (MAC-dependent cell lysis) assays; secretion analysis\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic expression and functional characterization of all four mutants with multiple readouts; single lab\",\n      \"pmids\": [\"30533526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"An antibody–CD59 fusion protein (IgG-CD59) targeted to cell surfaces via antigen binding provides complement protection specifically to antigen-positive cells but not bystander cells; CD59 must be positioned in close proximity to MAC formation sites for effective function, and non-GPI membrane attachment modes affect CD59 activity.\",\n      \"method\": \"Construction and expression of IgG-CD59 chimeric fusion proteins with CD59 at different Ig region positions; binding to dansyl-labeled CHO cells; complement lysis protection assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution with targeted delivery establishing spatial requirement; single lab\",\n      \"pmids\": [\"9884334\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD59 is a GPI-anchored glycoprotein that protects host cells from complement-mediated lysis by binding directly to the β-hairpins of C8 (α-chain) and C9 (C9b domain) within assembling MAC complexes, forming an intermolecular β-sheet that blocks membrane perforation and halts C9 polymerization (established by radiolabel binding assays and cryo-EM structures); it additionally functions as a CD2 co-ligand mediating T cell adhesion and costimulation (requiring N-glycosylation at Asn18 and CD58 co-expression), as an NK cell co-receptor physically associated with NKp46/NKp30 whose GPI anchor-dependent signaling enhances cytotoxicity, and as an intracellular regulator of insulin secretion through alternatively spliced non-GPI isoforms (IRIS-1/2) that interact with exocytotic SNARE proteins VAMP2, Syntaxin-1, and SNAP25 in pancreatic β-cells; its expression is transcriptionally regulated by p53, REST, and SOX2, and loss-of-function (genetic KO or human mutations) causes spontaneous intravascular hemolysis and, in humans, demyelinating neuropathy due to uncontrolled MAC formation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD59 is a GPI-anchored cell-surface glycoprotein whose primary role is to protect host cells from complement-mediated lysis by restricting assembly of the membrane attack complex (MAC) [#0, #2]. It acts through direct protein-protein contacts, binding specifically to the alpha-chain of C8 and the C9b domain of C9 but not other complement subunits [#0]; cryo-EM of inhibited C5b8 and C5b9 precursors shows that CD59 engages the pore-forming \\u03b2-hairpins of C8 to form an intermolecular \\u03b2-sheet that prevents membrane perforation and deflects cascading C9 \\u03b2-hairpins to halt polymerization [#1]. This protective function is physiologically essential: CD59 knockout mice undergo spontaneous intravascular hemolysis from MAC-mediated erythrocyte destruction [#2], and a homozygous p.Cys89Tyr mutation that prevents CD59 surface localization causes congenital chronic hemolysis with relapsing demyelinating polyneuropathy in humans [#26], with all characterized congenital mutants failing to inhibit MAC formation [#27]. Complement inhibition requires correct membrane positioning rather than glycosylation, since unglycosylated and even transmembrane-anchored CD59 retain inhibitory activity when appropriately localized [#10, #23, #28]. Beyond complement regulation, CD59 serves several signaling and adhesion roles: it is a second ligand for the T-cell receptor CD2, driving adhesion and CD58-dependent, Asn18-glycosylation-dependent costimulation [#3, #6]; it physically associates with the NK natural cytotoxicity receptors NKp46 and NKp30 and enhances cytotoxicity through GPI-anchor-dependent signaling [#7, #11]; and CD59 cross-linking triggers death signaling via APO2L/TRAIL secretion in T cells and Syk-dependent necroptosis in erythrocytes [#12, #20]. A distinct intracellular function is exercised by alternatively spliced non-GPI cytosolic isoforms (IRIS-1/IRIS-2) that bind the exocytotic SNARE proteins VAMP2, Syntaxin-1, and SNAP25 to drive regulated insulin secretion in pancreatic \\u03b2-cells [#8, #9]. CD59 is also exploited as a receptor by the CD59-dependent cholesterol-dependent cytolysins intermedilysin and vaginolysin, which bind CD59 to coordinate prepore assembly [#18, #19]. Its expression is transcriptionally controlled by p53, REST, and SOX2 [#15, #16, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established the molecular basis of complement inhibition by defining exactly which MAC components CD59 contacts, moving the field from a phenomenological 'protectin' to a defined molecular interaction.\",\n      \"evidence\": \"Radiolabeled CD59 binding assays, ligand blotting of C8 subunits, and proteolytic mapping of C9 in vitro\",\n      \"pmids\": [\"1377690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural mechanism of how binding blocks pore formation\", \"Stoichiometry within an assembling MAC not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Identified a complement-independent function of CD59 as a CD2 ligand, revealing CD59 as an adhesion and immune-signaling molecule rather than solely a complement regulator.\",\n      \"evidence\": \"CHO transfection, antibody-blockable rosette assays, radiolabeled CD59 binding to CD2+ cells, and CD2R epitope induction\",\n      \"pmids\": [\"1385156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish downstream signaling consequences\", \"Physiological relevance versus complement role unaddressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed CD59 functions in detergent-resistant GPI-anchored membrane complexes containing CD55 and kinase activity, hinting at organized membrane signaling platforms.\",\n      \"evidence\": \"Co-immunoprecipitation with anti-CD59/anti-CD55 and kinase activity assay of immunoprecipitates from HPB ALL cells\",\n      \"pmids\": [\"1715364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase not identified\", \"Complex composition not fully characterized\", \"Single Co-IP approach\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrated direct costimulatory activity of CD59 in T-cell activation, distinguishing it from a passive adhesion molecule.\",\n      \"evidence\": \"Single and double CHO transfectants in rosette and T-cell proliferation assays with submitogenic PHA + IL-1\",\n      \"pmids\": [\"1370512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of synergy with CD58 unresolved at this stage\", \"Single lab\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined the molecular requirements for CD59 costimulation, establishing dependence on CD58 co-expression and Asn18 N-glycosylation.\",\n      \"evidence\": \"CHO transfectants with site-directed Asn18 mutagenesis, proliferation and IL-2 secretion assays with fixed transfectants\",\n      \"pmids\": [\"7521361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the signaling cascade downstream of costimulation\", \"Contrast with glycosylation-independent complement function not reconciled mechanistically\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that the GPI anchor is dispensable for complement inhibition, separating membrane attachment mode from inhibitory function.\",\n      \"evidence\": \"Retroviral transduction of transmembrane CD59 into GPI-deficient PNH B cells, complement lysis and PI-PLC assays\",\n      \"pmids\": [\"7522635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GPI-anchored CD59 could not be expressed on GPI-deficient L cells, limiting direct comparison\", \"Spatial positioning requirement not yet defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Confirmed N-glycosylation is not required for complement-inhibitory activity, dissociating the glycan requirement seen in costimulation from the complement role.\",\n      \"evidence\": \"Asn-16 glycosylation-site mutagenesis of rat CD59 expressed in CHO cells with multi-species complement lysis assays\",\n      \"pmids\": [\"9176120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Performed in rat CD59; species generalization not formally tested in human\", \"Effect on non-complement functions not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that effective complement inhibition requires CD59 positioned in close proximity to MAC assembly sites, defining a spatial constraint on its activity.\",\n      \"evidence\": \"IgG-CD59 chimeric fusion proteins targeted to antigen-positive CHO cells with complement protection assays\",\n      \"pmids\": [\"9884334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative distance/proximity threshold not defined\", \"Bystander protection limits not generalized to native tissue\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Provided in vivo proof that CD59 is physiologically required to protect erythrocytes from complement, validating the biochemical model in a whole-organism context.\",\n      \"evidence\": \"CD59-knockout mice with acidified serum lysis test, reticulocyte counts, plasma/urine hemoglobin, and cobra venom factor challenge\",\n      \"pmids\": [\"11435315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address non-erythroid or signaling functions in vivo\", \"Compensation by other complement regulators not evaluated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified CD59 as an NK cell co-receptor physically and functionally coupled to natural cytotoxicity receptors, extending its immune signaling role.\",\n      \"evidence\": \"Co-IP with NKp46/NKp30, anti-CD59 cytotoxicity assays, and CD3\\u03b6 phosphorylation analysis\",\n      \"pmids\": [\"14635045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect association with NCRs not resolved\", \"Endogenous ligand for this co-receptor function unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed CD59-driven NK enhancement requires GPI-anchor-dependent signaling and is glycosylation-independent, mechanistically distinguishing the signaling pathway from membrane raft localization.\",\n      \"evidence\": \"CD59 anchor variants (GPI, BiMP, transmembrane) in U937 cells, NK cytotoxicity, calcium flux after cross-linking, and lipid raft fractionation\",\n      \"pmids\": [\"16493049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of GPI-coupled signaling intermediates not defined\", \"Link to NCR association not mechanistically integrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified p53 as a transcriptional regulator of CD59, connecting complement protection to tumor-suppressor and stress signaling.\",\n      \"evidence\": \"In vitro p53 binding to CD59 promoter elements, siRNA knockdown with CD59 Western blot, and acetylation analysis in HeLa cells\",\n      \"pmids\": [\"16489052\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vivo promoter occupancy not shown\", \"Physiological context of p53-CD59 axis not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed REST represses neuronal CD59, and that relieving this repression protects neurons from complement, linking CD59 regulation to neural cell vulnerability.\",\n      \"evidence\": \"REST-derived peptide transfection in neuroblastoma and human neurons with CD59 expression and complement lysis assays\",\n      \"pmids\": [\"19884909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct REST binding to CD59 regulatory regions not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed that CD59 cross-linking actively signals cell death via selective APO2L/TRAIL secretion, recasting CD59 as a death-signaling receptor in T cells.\",\n      \"evidence\": \"Anti-CD59 cross-linking on Jurkat cells with FasL/TRAIL/APO2L blocking antibodies and confirmation in normal T-cell blasts\",\n      \"pmids\": [\"10760796\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proximal signaling from CD59 to APO2L secretion not defined\", \"Physiological trigger of cross-linking unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that CD59-restricted MAC formation protects against vascular pathology, linking complement control to aortic aneurysm and MMP/AP-1/NF-kB signaling.\",\n      \"evidence\": \"CD59 knockout and human CD59 transgenic mice in angiotensin II aneurysm model with C9, MMP, and AP-1/NF-kB readouts plus in vitro MAC stimulation\",\n      \"pmids\": [\"20212283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type driving the protective effect not isolated\", \"Whether sublytic MAC versus lysis dominates the phenotype unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Uncovered an unexpected intracellular role for CD59 in regulated insulin exocytosis through SNARE binding, revealing function beyond the cell surface.\",\n      \"evidence\": \"Co-IP with VAMP2 and Syntaxin-1, siRNA silencing, TIRF imaging, PI-PLC cleavage, and insulin secretion assays in \\u03b2-cells\",\n      \"pmids\": [\"24726385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular form of intracellular CD59 not yet defined at this stage\", \"Mechanism of SNARE regulation not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a Syk-dependent receptor signaling pathway by which CD59 engagement drives erythrocyte necroptosis, mechanistically linking CD59 to programmed cell death.\",\n      \"evidence\": \"CD59 cross-linking and toxin treatment with Syk inhibition, FasL blocking, and phosphorylation analysis of Band 3, RIP1, RIP3\",\n      \"pmids\": [\"26018734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance to in vivo hemolysis not established\", \"Coupling of CD59 to Syk activation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the structural mechanism by which CD59-dependent cholesterol-dependent cytolysins exploit CD59, including a proline selectivity switch ensuring CD59 binding precedes cholesterol engagement.\",\n      \"evidence\": \"Crystal structures of VLY:CD59 and ILY:CD59, SAXS, molecular dynamics, and EM/AFM of prepore intermediates\",\n      \"pmids\": [\"27499440\", \"27910935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Host benefit or consequence of serving as a toxin receptor not addressed\", \"How CD59 release during pore maturation is triggered structurally not fully defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified SOX2 as a CD59 transcriptional activator that shields cancer stem cells from complement, connecting CD59 regulation to tumorigenesis and immune evasion.\",\n      \"evidence\": \"CD59/SOX2 siRNA silencing, complement lysis assays, and xenograft tumorigenesis in nude mice\",\n      \"pmids\": [\"28017655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SOX2 binding at the human CD59 locus not fully mapped\", \"Cancer-type generality not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Systematically characterized all known congenital CD59 mutations, showing they all yield nonfunctional protein that fails to inhibit MAC despite varied surface trafficking and antibody recognition.\",\n      \"evidence\": \"Expression of four mutants with myc-tag and anti-CD59 labeling, glycosylation Western blots, secretion analysis, and complement lysis assays\",\n      \"pmids\": [\"30533526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for antibody non-recognition of surface-reaching mutants not solved\", \"Genotype-phenotype variability not explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked CD59 deficiency to radioresistance via Src kinase signaling and impaired DNA damage repair, indicating CD59 influences intracellular stress responses in cancer.\",\n      \"evidence\": \"CD59 knockdown/overexpression in ESCC cells with gamma-H2AX, cell cycle, senescence, phospho-Src Y416 analysis, and Src inhibitor treatment\",\n      \"pmids\": [\"30166523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between CD59 and Src activation not defined\", \"Surface versus intracellular CD59 contribution not distinguished\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed CD59 within the LecA-Gb3 lipid raft domain co-opted for P. aeruginosa invasion, implicating CD59-containing membrane domains in host-pathogen entry.\",\n      \"evidence\": \"LecA pulldown with mass spectrometry and CD59 depletion bacterial invasion assays\",\n      \"pmids\": [\"33555391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CD59 is functionally required or a bystander raft constituent not fully resolved\", \"Direct CD59-LecA interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved the molecular identity of intracellular insulin-regulating CD59 as alternatively spliced non-GPI cytosolic isoforms (IRIS-1/2) that bind SNAREs and are required for secretion, completing the mechanistic picture of CD59 in \\u03b2-cell exocytosis.\",\n      \"evidence\": \"Splice-variant cloning, Co-IP with VAMP2/SNAP25, insulin-granule colocalization, CD59-KO rescue, and CRISPR knockout of mouse intracellular isoforms\",\n      \"pmids\": [\"35666870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise step in SNARE assembly modulated by IRIS isoforms not defined\", \"Relevance to human diabetes not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided the high-resolution structural mechanism of MAC inhibition, showing CD59 forms an intermolecular beta-sheet with C8 hairpins and deflects C9 hairpins to halt polymerization.\",\n      \"evidence\": \"Cryo-EM of C5b8:CD59 and C5b9:CD59 with cellular lysis assays and molecular dynamics simulations\",\n      \"pmids\": [\"36797260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of CD59 needed per MAC in vivo not addressed\", \"Kinetics of CD59 capture during rapid assembly not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CD59's distinct activities \\u2014 surface complement inhibition, GPI-coupled co-receptor signaling, death-pathway triggering, and intracellular SNARE-mediated exocytosis \\u2014 are coordinated and physiologically prioritized within and across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking GPI-anchored signaling to defined intracellular effectors\", \"Regulation of splice-isoform choice between canonical CD59 and IRIS isoforms not characterized\", \"Relative in vivo contribution of complement-dependent versus complement-independent functions not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 27]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 11]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [18, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 26]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 20]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12, 20]}\n    ],\n    \"complexes\": [\"MAC (C5b-9) inhibitory complex\", \"lipid raft / GPI-anchored signaling complex\"],\n    \"partners\": [\"C8\", \"C9\", \"CD2\", \"CD58\", \"NKp46\", \"NKp30\", \"VAMP2\", \"STX1A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}